Alternative Therapies to Bacillus Calmette-Guérin Shortage for Nonmuscle Invasive Bladder Cancer in Brazil and Other Underdeveloped Countries: Management Considerations

Bacillus Calmette-Guérin (BCG) plays a cornerstone role in the management of nonmuscle invasive urothelial carcinoma of the bladder. However, there has been a worldwide intermittent BCG shortage in recent years that may affect the care of patients with bladder cancer and pose difficult clinical decisions to urologists and clinical oncologists. This literature review aims to clarify alternatives to BCG during a shortage and propose measures to replace BCG, mainly in Brazil and probably in other low- and middle-income countries, where not all studied and commonly suggested treatments are available.

• Publication year

  2019

• Venue

  Journal of Global Oncology

• Publication date

  2019-08-27

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1200/JGO.19.00112PMID 31454284PMCID 6776038
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bladder cancer, version 3.2020

  2020cited by this paper
• Cancer statistics, 2018

  2018cited by this paper
• Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial

  2018influential reference
• What to do during Bacillus Calmette–Guérin shortage? Valid strategies based on evidence

  2018cited by this paper
• Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naïve High-grade Non-muscle-invasive Bladder Cancer.

  2018cited by this paper
• Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.

  2017cited by this paper
• Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity

  2017cited by this paper
• Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

  2017cited by this paper
• Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.

  2016cited by this paper
• Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from

  2016cited by this paper
• Comparing long‐term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy

  2016cited by this paper
• Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.

  2015cited by this paper
• Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.

  2014cited by this paper
• Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

  2013cited by this paper
• Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.

  2012cited by this paper
• 1655 INTRAVESICAL GEMCITABINE VERSUS BACILLUS CALMETTE-GUERIN ( BCG) IN TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER: SHORT TERM COMPARATIVE STUDY

  2011cited by this paper
• Maintenance therapy with bacillus Calmette‐Guérin Connaught strain clearly prolongs recurrence‐free survival following transurethral resection of bladder tumour for non‐muscle‐invasive bladder cancer

  2011cited by this paper
• Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.

  2010cited by this paper
• Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladd

  2010cited by this paper
• Gemcitabine versus bacille Calmette‐Guérin after initial bacille Calmette‐Guérin failure in non‐muscle‐invasive bladder cancer

  2010cited by this paper
• Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladd

  2010cited by this paper
• The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.

  2010cited by this paper
• Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.

  2010cited by this paper
• Bacillus Calmette-Guérin versus Gemcitabine for Intravesical Therapy in High-Risk Superficial Bladder Cancer: A Randomised Prospective Study

  2010cited by this paper
• An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

  2009cited by this paper
• Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?

  2008cited by this paper
• The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials.

  2008cited by this paper
• History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story.

  2008cited by this paper
• The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma.

  2007cited by this paper
• A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.

  2007cited by this paper
• Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

  2006cited by this paper
• Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.

  2005cited by this paper
• Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer

  2005cited by this paper
• Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials

  2004cited by this paper
• Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.

  2002cited by this paper
• Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer

  2002cited by this paper
• What Is the Optimal Regimen for BCG Intravesical Therapy?

  2000cited by this paper
• Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

  2000cited by this paper
• The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.

  1996cited by this paper
• Bacillus calmette—Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four‐year results

  1995cited by this paper
• Improving the efficacy of BCG immunotherapy by dose reduction.

  1995cited by this paper
• Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group.

  1995cited by this paper
• A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.

  1987cited by this paper
• Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.

  1981cited by this paper
• Carcinoma in situ of the bladder.

  1980cited by this paper
• Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

  1976cited by this paper
• INTRACAVITARY BACILLUS CALMETTE‐GUERIN IN THE TREATMENT OF SUPERFICIAL BLADDER TUMORS

  1976cited by this paper

• Urinary microbiome and metabolomic profiling reveal propionic acid as an enhancer of BCG immunotherapy in bladder cancer.

  2026cites this paper
• Multicenter Retrospective Registry Study on BCG Use in Non-Muscle Invasive Bladder Cancer in Latin America: BLATAM (Bladder Cancer in Latin America) Group

  2025cites this paper
• Challenges and opportunities in NMIBC management across Latin America: insights from healthcare providers and a patient advocacy group

  2024influential citation
• Increased risk of bladder cancer recurrence due to bacillus Calmette-Guérin shortage in Brazil

  2024cites this paper
• Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols

  2024cites this paper
• Strategies for Overcoming Immune Evasion in Bladder Cancer

  2024cites this paper
• Implementation of new treatments for BCG-unresponsive non-muscle-invasive bladder cancer. Considerations in Latin America.

  2024cites this paper
• Urologic Cancer Drug Costs in Low- and Middle-Income Countries

  2024cites this paper
• Interruption of BCG Therapy for NMIBC During COVID-19 Crisis, Dilemma in Its Continuation: a Review of Available Evidence and Suggested Management Strategies

  2023cites this paper
• Access of new systemic therapies for Genito-urinary cancers in low-middle income countries

  2022cites this paper
• Oncologic outcomes of Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer: A meta-analysis

  2022cites this paper
• Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage

  2022cites this paper
• Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study

  2021cites this paper
• Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?

  2021cites this paper
• Impact of the COVID-19 Pandemic on the Urologist’s clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period

  2020cites this paper
• Dutch translation and linguistic validation of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™)

  2020cites this paper
• Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update

  2020influential citation